Clinical trials: Crohns Disease
Crohn's Disease
Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease
This is a phase 2, randomized, double-blind, multicenter study to assess the therapeutic efficacy, safety, and mechanisms of omilancor (BT-11) in patients with moderate to severe Crohn's Disease (CD).
- Trial name
- NCT05057273
- Testing
- BT-11, Active comparator
- Sponsor
- NImmune Biopharma
Ulcerative Colitis, Crohn's Disease
Predicting Medication Response for Autoimmune Disease
Coral is conducting a large study comparing and predicting the relative effectiveness of different medications for autoimmune patients.
- Conditions
- Ulcerative Colitis, Crohn's Disease, Psoriasis, Rheumatoid Arthritis
- Trial name
- REEF (NCT04995783)
- Testing
- Coral FRS test
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Coral Genomics, Inc.
Crohn's Disease
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
The purpose of this study is to monitor safety outcomes of patients who have taken Cimzia® as compared to a non- Cimzia® control population.
- Trial name
- SECURE (NCT00844285)
- Testing
- Cimzia
- Where
- 197 sites in United States
- Volunteers
- 3,072 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Arthritis, Rheumatoid (RA), Axial Spondyloarthritis (axSpA)
A Real-world Study of Imraldi® Use
The primary objective of this study is to evaluate candidate predictors of persistence on adalimumab (Imraldi®) participants diagnosed with immune-mediated inflammatory disease in Europe (EU).
- Conditions
- Arthritis, Rheumatoid (RA), Axial Spondyloarthritis (axSpA), Arthritis, Psoriatic (PsA), Crohn's Disease (CD)
- Trial name
- PROPER (NCT04089514)
- Testing
- Adalimumab
- Where
- 54 sites in Belgium, Germany and 4 more
- Volunteers
- 1,000 people
- Sponsor
- Biogen
Crohn's Disease
A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease
The proposed study is a randomized, double-blind, placebo-controlled, multi-center Phase II study to investigate the safety and efficacy of SHR0302 in patients with moderate to severe active Crohn's Disease.
- Trial name
- NCT03677648
- Testing
- SHR0302
- Where
- 82 sites in United States, China and 2 more
- Volunteers
- 112 people
- Sponsor
- Reistone Biopharma Company Limited
Crohn's Disease
Efficacy and Safety of TD-1473 in Crohn's Disease
A Phase 2 study to evaluate the efficacy, safety and tolerability of TD-1473 in subjects with moderately-to-severely active Crohn's Disease with up to 48 weeks of treatment.
- Trial name
- DIONE (NCT03635112)
- Testing
- TD-1473
- Where
- 178 sites in United States, Australia and 20 more
- Volunteers
- 167 people
- Sponsor
- Theravance Biopharma
Crohn's Disease
Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.
The purpose of this study is to assess the safety and efficacy of vedolizumab intravenous (IV) infusion as induction treatment in Chinese participants with moderately to severely active Crohn's disease (CD) at Week 10.
- Trial name
- NCT03234907
- Testing
- Vedolizumab IV
- Where
- 29 sites in China
- Volunteers
- 215 people
- Sponsor
- Takeda
Crohn's Disease
A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease
This study is a multicenter, open-label, uncontrolled, multiple ascending dose (MAD) study to evaluate mainly the safety and tolerability of 12-week repeated intravenous administration of E6011.
- Trial name
- NCT02039063
- Testing
- E6011 2 mg/kg, E6011 5 mg/kg, E6011 10 mg/kg
- Where
- 17 sites in Japan
- Volunteers
- 28 people
- Sponsor
- EA Pharma Co., Ltd.
Crohn Disease, Ulcerative Colitis
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
National, prospective, multicentre observational study designed for eligible patients treated with Inflectra. Its objectives are to describe under real conditions of use, the profile of patients treated with Inflectra and the…
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- ReFLECT (NCT02925338)
- Testing
- QOL questionaire
- Where
- 67 sites in France
- Volunteers
- 1,431 people
- Sponsor
- Pfizer
Inflammatory Bowel Disease (IBD), Ulcerative Colitis
A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD)
This is a non-interventional, retrospective study of adult participants with IBD. IBD consists of either ulcerative colitis (UC) or Crohn's disease (CD).
- Conditions
- Inflammatory Bowel Disease (IBD), Ulcerative Colitis, Crohn's Disease
- Trial name
- NCT05596422
- Where
- 4 sites in Taiwan
- Volunteers
- 423 people
- Sponsor
- Takeda
Inflammatory Bowel Diseases, Ulcerative Colitis
Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease
Ulcerative colitis and Crohn's disease are the commonest types of inflammatory bowel disease (IBD). Both conditions range in severity from no symptoms to being potentially fatal.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
- Trial name
- NCT03836612
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 95,055 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Crohn's Disease
Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease
ISIS 2302 is an antisense oligonucleotide drug that reduces the production of a specific protein called intercellular adhesion molecule (ICAM-1), a substance that plays a significant role in the increase of inflammation.
- Trial name
- NCT00048113
- Testing
- Alicaforsen
- Where
- 30 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Crohn's Disease
A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in adults with moderately and severely active Crohn's disease (CD).
- Trial name
- U-EXCEL (NCT03345849)
- Testing
- Upadacitinib
- Where
- 432 sites in United States, Argentina and 47 more
- Volunteers
- 526 people
- Sponsor
- AbbVie
Crohn Disease
A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease
This is a multicenter, Phase 3, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of etrolizumab compared with placebo during induction and maintenance treatment of moderately to severely…
- Trial name
- BERGAMOT (NCT02394028)
- Testing
- Etrolizumab
- Where
- 327 sites in United States, Argentina and 31 more
- Volunteers
- 1,035 people
- Sponsor
- Hoffmann-La Roche
Healthy Participants
Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants
This is a Phase I, single-centre, open-label, parallel-group, single dose study to evaluate the pharmacokinetics, safety and tolerability of Brazikumab in healthy male and female Chinese participants and healthy male and female…
- Trial name
- NCT05033431
- Testing
- Brazikumab
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Crohn Disease
A Study of Real-World Outcomes of People With Crohn's Disease (CD)
The main aim of this study is to compare long-term remission in participants receiving vedolizumab (VDZ) and those receiving ustekinumab (UST). In this study, the study doctors will review each participant's past medical records.
- Trial name
- EVOLVE (NCT05056441)
- Where
- 31 sites in Australia, Belgium and 1 more
- Volunteers
- 623 people
- Sponsor
- Takeda
Crohn's Disease
A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease
The primary objective of this study is to establish the safety and tolerability of multiple ascending doses (MAD) of foralumab enteric coated capsules administered orally, once daily for 5 days per week over 2 weeks in…
- Trial name
- NCT05028946
- Testing
- Foralumab
- Sponsor
- Tiziana Life Sciences LTD
Arthritis, Rheumatoid, Spondylitis, Ankylosing
One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study
A study to describe the one-year persistence in participants treated by Flixabi (infliximab) or Imraldi (Adalimumab) as prescribed by the physician for each of the 5 following indications: Rheumatoid Arthritis (RA), Ankylosing…
- Conditions
- Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Crohn's Disease
- Trial name
- PERFUSE (NCT03662919)
- Testing
- Infliximab, Adalimumab
- Where
- 60 sites in France
- Volunteers
- 2,274 people
- Sponsor
- Biogen
Crohn's Disease
A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease
The purpose of this study is to evaluate the safety and effectiveness of the study drug Mirikizumab in participants with active Crohn's Disease.
- Trial name
- SERENITY (NCT02891226)
- Testing
- Mirikizumab
- Where
- 108 sites in United States, Australia and 12 more
- Volunteers
- 191 people
- Sponsor
- Eli Lilly and Company